Abstract
Microarrays have identified thousands of dysregulated genes in the brains of patients with Alzheimer’s disease (AD); yet identifying the best gene candidates to both model and treat AD remains a challenge. To this end, we performed a meta-analysis of microarray data from the frontal cortex and cerebellum of AD patients, followed by an artificial-intelligence driven approach to identify the top AD gene candidates. In the frontal cortex, gene candidates included mitochondrial complex V subunits: ATP5J, ATP5L and ATP5H. In the cerebellum, the top candidate was SC5D, which is involved in cholesterol biosynthesis and catabolism. An important finding was that there was no overlap in dysregulated pathways between the frontal cortex and cerebellum, suggesting that pathophysiological mechanisms in AD are brain-region specific. Combined, these results have significant implications for future models and therapeutic strategies in AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Macquarie University Research Acceleration Scheme Grant (MQRAS 173983854) awarded to C.A.F. and A.S.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used publicly available datasets from the Gene Expression Omnibus (GEO) database. The accession numbers for the datasets are: GSE44770, GSE33000, and GSE44768.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors